Background_01

News

News and press releases:

Quantib invites you to its ECR booth

24-02-2017

Quantib will be at the European Congress of Radiology. Come visit us at booth G/22, Expo Gallery - First Level.

Magnus Carlsen simultaneous chess for Erasmus MC - Sophia

02-02-2017

Last Monday world champion Magnus Carlsen played simultaneous chess against 36 enthousiasts. It was a charity event and he helped to raise almost 40.000 euro for child care research in the Erasmus MC Sophia children's hospital in Rotterdam. Quantib sponsored one player. picture

Quantib Brain 1.2 cleared for U.S. market

12-01-2017

The upgrade of Quantib Brain is cleared by the U.S. Food and Drug Administration (FDA). Quantib Brain 1.2 enables comparison of multiple MRI exams of the same patient. This longitudinal analysis will quantify volume differences in brain tissues and white matter hyperintensities. Exams are displayed side-by-side and white matter hyperintensities are automatically labeled as consistent, new or disappearing.

Quantib R&D engineer elected Simon Stevin Gezel

24-11-2016

Quantib R&D engineer Valerio Fortunati was elected Simon Stevin Gezel 2016. The title Simon Stevin Gezel is an honorary title the Techonology Foundation STW grants annualy to a promising young researcher for his PhD research on a STW project. read more

Quantib invites you to its RSNA booth

17-11-2016

Quantib will be at the RSNA annual meeting 2016. Come visit us at Booth 8318, Hall B! We are located in The Netherlands Presents Pavilion.

Rabobank lists Quantib in medical technology top 5

08-11-2016

Rabobank published a top 5 of Dutch companies with today's best ideas in the medical technology sector. Quantib is in it. infographic [pdf]

Quantib Receives Approval from U.S. and European Regulators to Market Quantib Brain

08-08-2016

Quantib B.V. has received approval from U.S. and European regulators to market its first product, Quantib Brain 1.1 in their jurisdictions. The company received European Union CE marking and clearance from the U.S. Food and Drug Administration for its advanced analytical software. Quantib Brain 1.1 automatically extracts biomarkers from brain MRI scans. Such neurobiomarkers are strongly correlated with the onset and development of neurodegenerative and inflammatory diseases such as Alzheimer's and multiple sclerosis. press release [pfd]

Prof. Niessen awarded Simon Stevin Meester prize

08-07-2015

Technology foundation STW has awarded Prof. Dr. Niessen, professor of Medical Image Analysis at Erasmus MC and TU Delft and Chief Scientific Officer of Quantib, with the title of Simon Stevin Meester 2015. The Simon Stevin Meester prize is the biggest award for technical and scientific research in the Netherlands. read more [Dutch only]

Quantib Receives ISO 13485 Certification

06-04-2014

On 6 April 2014 Quantib B.V. was ISO 13485:2012 certified by DEKRA Certification B.V. This confirms that our quality management system (QMS) meets the comprehensive QMS requirements for the design and manufacture of medical devices and enables us to apply for CE marks and/or U.S. FDA approval for solutions we develop.

Radio Interview (in Dutch)

Interview in Dutch
14-06-2013

Chief Scientific Officer Dr. Wiro Niessen discusses Quantib with Dutch radio station BNR. You can listen to the interview at BNR’s website.

Erasmus MC and GE Healthcare Collaborate to Improve Diagnosis of Neurological Disorders

To this end, both organizations have established a collaborative project with the Erasmus MC spin-off company Quantib.
29-05-2013

Erasmus MC and GE Healthcare announced their collaboration to improve the diagnosis of neurological disorders such as multiple sclerosis, Alzheimer's, and Parkinson's disease through Quantib B.V., a spin-off of Erasmus MC.

"Innovations and partnerships are necessary to improve and make healthcare more efficient," said Roland Teixeira, Country Executive of GE Benelux. "We hope that this project will be the start of more objective and quantitative analysis of images in hospitals worldwide, leading to better, earlier diagnosis of neurological disorders, creating savings for healthcare systems, and improving the quality of life for patients."
read more 


Contact us
for more information.